Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Equivalents: 2012-2024

Historic Cash & Equivalents for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $151.6 million.

  • Amphastar Pharmaceuticals' Cash & Equivalents rose 12.57% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.3 million, marking a year-over-year increase of 12.57%. This contributed to the annual value of $151.6 million for FY2024, which is 5.07% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Cash & Equivalents stood at $151.6 million for FY2024, which was up 5.07% from $144.3 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash & Equivalents peaked at $156.1 million during FY2022, and registered a low of $92.6 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $151.6 million (2024), whereas its average is $150.7 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Cash & Equivalents soared by 36.39% in 2021 and then declined by 7.56% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash & Equivalents (Yearly) stood at $92.6 million in 2020, then spiked by 36.39% to $126.4 million in 2021, then climbed by 23.54% to $156.1 million in 2022, then decreased by 7.56% to $144.3 million in 2023, then climbed by 5.07% to $151.6 million in 2024.